Previous 10 | Next 10 |
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute ( ...
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: ...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chem...
Genprex (GNPX) presents positive preclinical data for the combination of TUSC2 immunogene therapy (Reqorsa) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer ((NSCLC)). These data were presented at the AACR Meeting 2021. The first presentatio...
REQORSA Enhances Efficacy of Chemo-Immune Combination Therapy in KRAS-LKB1 Mutant NSCLC in Humanized Mice REQORSA Overcomes Resistance to Targeted Therapy Osimertinib Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a cl...
Top Biotech Penny Stocks To Watch If you are looking to invest in penny stocks, there has never been a better time than now. By definition, the term “ penny stock ” refers to stocks that trade under $5. Thanks to this, the low cost provides an interesting entry opportu...
Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...
Company overview to highlight novel gene therapies for cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with ca...
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-st...
Investor presentation to highlight novel gene therapies for cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...